By 2020, Chouinard’s discomfort with his ownership of the lucrative outdoor apparel brand was ramping up. While Patagonia has ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the ...

Wearable and implantable biosensors that can accurately detect biological molecules in a non- or minimally invasive manner ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Greenland's pro-business opposition Demokraatit party, which favours a slow approach to independence from Denmark, won a ...

One of the losers of today's trading session was Novo Nordisk A/S. Shares of the Pharmaceutical company plunged -9.8%, and some investors may be wondering if its price of $78.63 would make a good ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...